{"entity":{"id":"nct06637423","kind":"trial","name":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)","aka":[],"tldr":"A phase 1/2 trial of Sacituzumab tirumotecan in bladder & urothelial cancer, run by Merck Sharp & Dohme LLC, now recruiting.","summary":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) is a phase 1/2 interventional study registered as NCT06637423 by Merck Sharp & Dohme LLC, with 32 participants planned, started 2024-12-20 and due to reach its primary completion in 2029-03-14. Interventions recorded: Sacituzumab tirumotecan, Rescue medication and Supportive care measures.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06637423","url":"https://clinicaltrials.gov/study/NCT06637423"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":["sacituzumab-tirumotecan"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06637423","phase":"1/2","setting":"A Phase 1/2 Open-label Clinical Study to Evaluate the Safety and Efficacy of Intravesical Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (NMIBC)","sponsor":"Merck Sharp & Dohme LLC","enrolled":32,"outcomes":[]},"route":"/trials/nct06637423/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"drug":[{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}